Table 1.
Relation of ADH2, ADH3, and ALDH2 polymorphisms to colorectal cancer risk
| Genotype | Cases (n, %) | Controls (n, %) | Adjusted OR (95% CI) † |
|---|---|---|---|
| ADH2 Arg47His ‡ | |||
| His/His (fast) | 345 (50.8) | 452 (58.1) | 1.00 (referent) |
| Arg/His | 294 (43.3) | 289 (37.1) | 1.32 (1.06–1.64) |
| Arg/Arg (slow) | 40 (5.9) | 37 (4.8) | 1.36 (0.84–2.20) |
| ADH3 Ile349Val § | |||
| Ile/Ile (fast) | 609 (88.9) | 706 (90.9) | 1.00 (referent) |
| Ile/Val | 74 (10.8) | 68 (8.7) | 1.29 (0.91–1.83) |
| Val/Val (slow) | 2 (0.3) | 3 (0.4) | 0.77 (0.13–4.70) |
| ALDH2 Glu487Lys | |||
| Glu/Glu | 400 (58.4) | 416 (53.5) | 1.00 (referent) |
| Glu/Lys | 257 (37.5) | 309 (39.7) | 0.89 (0.71–1.13) |
| Lys/Lys (null activity) | 28 (4.1) | 53 (6.8) | 0.55 (0.33–0.93) |
†
Adjusted for sex, 5‐year age class, area, and alcohol use.
‡
‡ Six cases were excluded because of undetermined genotype.
§
§ One control was excluded because of undetermined genotype. CI, confidence interval; OR, odds ratio.